Oncology Central

Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies

0

Encouraging data from the clinical trials of inhibiting programmed cell death-1 (PD-1)/programmed death-ligand (PD-L) pathway in recent years suggests improvement in the efficiency of immunotherapy in lung cancer. The interaction between PD-1 and its ligands, PD-L1 and PD-L2 as the second signal of the activation of T cells leads to the downregulation of T-cell responses and inhibit cytokine production.

To view restricted content, please:
Share:

Leave A Comment